18'7'2004 Internationales Forum zur Anwendung von Taheebo Osaka Japan

1
18.7.2004Internationales Forum zur Anwendung von
TaheeboOsaka / Japan
2
ZENTRUM NOSOMIALLGEMEINMEDIZIN, ONKOLOGIE,
NATURHEILVERFAHRENÄRZTLICHE LEITUNG Dr.Dr.
HELMUT BACOWSKY

• 1200 Wien, Sachsenplatz 9/30
• Tel. [phone], Fax [phone]
• E-Mail nosomi_at_nosomi.at www.nosomi.at

3
Short Report on Intratumoral Application of
Taheebo Extract in Combination with ECT
(Electro-Chemical-Therapy) in 18 Patients
suffering from Cancer of the Prostate

• Bacowsky H.

• www.nosomi.at

4
Cancer of the prostate Incidence Austria
2000 4.925 patients EU 42,61 cases / 100.000
inhabitants Mortality 14,65 /100.000

• (Statistic Austria, Gesundheitsbuch 2002).

5
Purpose of investigation

• Are there side effects when Taheebo-extract is
  injected directly into the prostate?
• Are there risks for incontinence ?
  impotence ? reoccurrence ? metastasis ?

• Is prolongation of remission possible?
• Is there a positive influence on quality of life?

www.nosomi.at
6
This investigation is based on individual cases,
no exclusions have been performed

• Each patient was informed thoroughly and in
  detail about risks concerning side effects,
  prognosis, relapse and possibility of metastasis
  compared with established therapies like
  operation, radiation, brachytherapy,
  hormonblockade.

7
Methode

• 18 patients, mean age 70,2 years (max.96 min.
  51years ) with prostate cancer, verified by
  biopsy
• Gleason score, mean 5,1 ranging from 3 to 7
• Bone metastasis present before treatment (3)
• Male hormone blockage before ECTTaheebo
  application (3)

• being continued after treatment (3)
• male hormone blockage after ECTTaheebo, new
  application (3)
• Chemotherapy, operation and radiation before
  ECTTaheebo application (0).

8
Status before treatment
9
ECT (Electro-Chemical-Therapy)

• ECT In the case of initial or progressed cancer
  of the prostate ECT provides a possible effective
  minimal invasive  treatment using electricity
  provided by a DC-device. After local anaesthesia
  2 electrodes made out of platin are inserted via
  the perineum into the prostate. Then a currency
  of 7-7.5 Volt is administered for about 40-50
  minutes depending on the size of the prostate. At
  the end of treatment the electrodes are removed.
  Sideeffects like mild haematuria or impairment of
  urination can be possible, but as we have seen in
  more than 57 patients so far, these side effects
  happened only in 2 cases.

10
Taheebo-extract

• was prepared by boiling down 30g Tabebuia av.
  powder (provided by Taheebo Japan Co.) with 500
  ml water in a glass jar for 40 minutes. Decoct
  and sediment was transferred into 10 ml vials,
  which were then sterilised at 120? C for 2 hours.
  Probes were tested on bacterial contamination
  (ARGE Graz) and analysed for content of
  Furan-Naphtochinon (Laboratories of Kyoto
  Prefectural University of Medicine). Each 10 ml
  vial contained 25mg Furan-Naphtochinon
• Immediately after ECT platin electrodes were
  removed and via syringe 5-10ml Tabebuia-extract
  was injected directly into the prostate
• PSA-levels were determined before treatment and
  every 6-8 months after therapy, sonographic and
  physical examination were done and Quality of
  life assessed by using a standard questionnaire
  (TOC)

11
Results
side effects
12
Results/??
30 months Observation/??????30??

• 3 patients out of 18 died, two patients due to
  additional chemotherapy performed in another
  clinic, 25 months and 30 months after
  ECT/Taheebo, one died of old age.
• 18 ???3????????2??????????????????????????????????
  25???30???????1?????????
• 6 patients underwent therapy with male hormone
  blocking agent
• 6??????????????????
• 3 already some time before treatment, because 2
  out of 3 had bone metastasis
• 3????????????????????????????????2????????????????
  

13
Results/??

• 3 received hormone blockade immediately after
  ECT/Taheebo.
• 3?????????????????????????????????
• 15 patients are still alive, no relapse or bone
  metastasis in those patients who had none before
  treatment, no marked progression in those 2
  patients with bone metastasis who were treated by
  hormone blockade and biphosphonate infusion at
  regular interval. One patient with bone
  metastasis before ECT/Taheebo therapy is stable
  with only slow progress observed, neither treated
  with a hormone blocking agent nor receiving
  biphosphonate infusions.
• 15?? ???????????????????????????????????????????2?
  ?????????????????????
• 12 patients without new metastasis during 30
  months of observation.
• 12???????????????????

14
Results
15
Results

• Individual PSA-levels differ in a wider range,
  elevation can be observed 4-6 months after
  treatment, due to manipulation of the prostate,
  dropping then or also rising again after 6-8
  months, though no visible metastasis are
  detectable in bones by szintigraphy.
• In those cases an examination by PET and
  molecular genetic evaluation of minimal residual
  cancer cells in peripheral blood will be done in
  a next step.

16
Results
Individual PSA level performance
17
Results
18
Summery/??ECT/Taheebo ?????????????????

• ECT/Taheebo ??

• Nearly pain free treatment
• No severe side effects
• No allergic reactions
• No impairment of libido and sexual function
• No incontinence
• No hospitalisation
• Patient is mobile immediately after treatment
• able to work within the next day
• low cost compared to operation, radiation

• ?????????????
• ????????????
• ?????????
• ????????????
• ?????
• ??????
• ?????????
• ?????? ????
• ??????

19
Summery/??ECT/Taheebo ?????????????????

• ECT/Taheebo ???

• Not yet approved method
• Too small number of patients with only 30 months
  of observation
• Further investigations necessary

• ??????????????
• ??????????????????30????
• ????????

20
Conclusion

• Prospective follow ups of patients of this pilot
  study are planned
• Data will be compared with patients treated with
  other methods
• Future investigations are planned to see, wether
  a combination of one or multiple injections in a
  certain interval combined with oral administered
  Taheebo can be helpful to suppress cancer growth
  in the prostate.
• Further Investigations will be directed using
  Taheebo extract in cell cultures on different
  wild type human cancer cell strains to
• show a possible direct cytostatic effect
• To elucidate the potential of Taheebo extract as
  an apoptosis inducing agent on a moleculargenetic
  level
• enhancing BAX protein reducing Bcl2 gene
  expression
• reducing MDR-RNA levels in vivo, minimising drug
  resistance, implementing the possibility of lower
  dosage of toxic chemo therapeutics.

21
ZENTRUM NOSOMIALLGEMEINMEDIZIN, ONKOLOGIE,
NATURHEILVERFAHRENÄRZTLICHE LEITUNG Dr.Dr.
HELMUT BACOWSKY

• 1200 Wien, Sachsenplatz 9/30
• Tel. [phone], Fax [phone]
• E-Mail nosomi_at_nosomi.at, www.nosomi.at